Certain drugs commonly used to treat enlarged prostate may also decrease the risk for dementia with Lewy bodies (DLB), according to a new study. The researchers think that a specific side effect of the drugs targets a biological flaw shared by DLB and other neurodegenerative diseases, raising the possibility that they may have broad potential for treating a wide range of neurodegenerative conditions.
Read more …Drugs for enlarged prostate may also protect against dementia with Lewy bodies
New research finds one copy of a protective genetic variant, APOE3 Christchurch, delayed onset of Alzheimer's disease for 27 members of a ~6,000-person family in Colombia at high risk for early-onset Alzheimer's in their 40s due to carrying the 'Paisa' (Presenilin-1 E280A) mutation. This work builds on a 2019 case report of a woman in this family who had two copies of the Christchurch variant and delayed Alzheimer's into her 70s. The new findings are the first to show that one copy of the variant confers some level of protection and increases the researchers' confidence that this genetic pathway should be targeted for therapeutics.
Read more …Study finds one copy of protective genetic variant helps stave off early-onset Alzheimer's disease
Researchers have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors use to survive.
Read more …Combination targeted treatment produces lasting remissions in people with resistant aggressive...